Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)ā¢ Click on a phase to view related trials
A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT06877624
- Locations
- š³š±
ICON plc. Van Swietenlaan 6, Groningen, Netherlands
A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT06714396
- Locations
- š³š±
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands, Netherlands
A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: QRL-101 Dose ADrug: QRL-101 Dose BDrug: Placebo
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06681441
- Locations
- š³š±
Centre for Human Drug Research, Leiden, Netherlands
A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT06532396
- Locations
- š³š±
ICON plc. Van Swietenlaan 6, Groningen, Netherlands
A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 88
- Registration Number
- NCT05667779
- Locations
- š³š±
ICON plc. Van Swietenlaan 6, Groningen, Netherlands
- Prev
- 1
- 2
- Next
News
Quiver Bioscience Secures $2.15M NIH Grant to Develop AI-Powered CNS Drug Safety Platform
Quiver Bioscience received a $2.15 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke to develop an integrated platform for predicting safety of CNS-targeted antisense oligonucleotide therapeutics.
QurAlis Reports Promising Phase 1 Data for QRL-101 in ALS and Epilepsy Biomarker Study
ā¢ QRL-101 demonstrated a dose-dependent, statistically significant decrease in SDTC, a biomarker linked to ALS disease progression and mortality, with effects approximately 50% greater than the previous Kv7 opener ezogabine. ā¢ The clinical trial showed significant impact on epilepsy-related biomarkers, including TMS-EMG intracortical facilitation and EEG spectral power changes, suggesting potential anti-seizure effects without sedation. ā¢ QurAlis plans to advance QRL-101 into proof-of-concept studies for both ALS and epilepsy based on the favorable safety profile and promising biomarker data from this healthy volunteer study.